ADC Therapeutics SA (NYSE:ADCT)
Income Statement
Mar-2022 | Dec-2021 | Sep-2021 | Jun-2021 | Mar-2021 | Dec-2020 | ||
---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue |
80
+137%
|
34
+101%
|
17
+350%
|
4
N/A
|
0
N/A
|
0
N/A
|
|
Gross Profit | |||||||
Cost of Revenue |
(2)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
|
Gross Profit |
78
+141%
|
33
+100%
|
16
+347%
|
4
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | |||||||
Operating Expenses |
(310)
|
(302)
|
(300)
|
(282)
|
(246)
|
(219)
|
|
Selling, General & Administrative |
(142)
|
(136)
|
(129)
|
(116)
|
(100)
|
(77)
|
|
Research & Development |
(175)
|
(165)
|
(170)
|
(166)
|
(146)
|
(142)
|
|
Depreciation & Amortization |
(2)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
|
Other Operating Expenses |
8
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(231)
+14%
|
(270)
+5%
|
(284)
-2%
|
(278)
-13%
|
(246)
-12%
|
(219)
N/A
|
|
Pre-Tax Income | |||||||
Interest Income Expense |
13
|
10
|
26
|
71
|
(9)
|
(27)
|
|
Non-Reccuring Items |
0
|
8
|
7
|
7
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
1
|
1
|
1
|
|
Pre-Tax Income |
(218)
+13%
|
(252)
0%
|
(251)
-26%
|
(200)
+21%
|
(254)
-3%
|
(246)
N/A
|
|
Net Income | |||||||
Tax Provision |
23
|
21
|
(1)
|
(0)
|
(0)
|
(0)
|
|
Income from Continuing Operations |
(195)
|
(230)
|
(252)
|
(200)
|
(254)
|
(246)
|
|
Net Income (Common) |
(195)
+15%
|
(230)
+9%
|
(252)
-26%
|
(200)
+21%
|
(254)
-3%
|
(246)
N/A
|
Balance Sheet
Mar-2022 | Dec-2021 | Sep-2021 | Jun-2021 | Mar-2021 | Dec-2020 | Sep-2020 | Jun-2020 | Dec-2019 | Jun-2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
431
|
467
|
530
|
372
|
383
|
439
|
494
|
349
|
116
|
182
|
|
Cash Equivalents |
431
|
467
|
530
|
372
|
383
|
439
|
494
|
349
|
116
|
182
|
|
Total Receivables |
27
|
30
|
16
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Accounts Receivables |
27
|
30
|
16
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
12
|
11
|
8
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
18
|
17
|
14
|
13
|
10
|
11
|
12
|
11
|
7
|
3
|
|
Total Current Assets |
488
|
525
|
568
|
394
|
393
|
451
|
506
|
359
|
123
|
185
|
|
PP&E Net |
11
|
11
|
12
|
11
|
11
|
5
|
5
|
6
|
6
|
7
|
|
PP&E Gross |
11
|
11
|
0
|
11
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Accumulated Depreciation |
2
|
2
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Intangible Assets |
14
|
14
|
13
|
12
|
10
|
10
|
10
|
9
|
8
|
8
|
|
Long-Term Investments |
39
|
41
|
44
|
46
|
47
|
48
|
0
|
0
|
0
|
0
|
|
Other Long-Term Assets |
31
|
27
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Assets |
582
-6%
|
618
-3%
|
638
+37%
|
464
+1%
|
462
-10%
|
514
-1%
|
522
+40%
|
374
+171%
|
138
-31%
|
201
N/A
|
|
Liabilities | |||||||||||
Accounts Payable |
16
|
12
|
12
|
15
|
12
|
5
|
6
|
7
|
3
|
1
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
8
|
8
|
8
|
7
|
4
|
5
|
4
|
4
|
1
|
1
|
|
Other Current Liabilities |
47
|
54
|
40
|
30
|
26
|
31
|
23
|
20
|
16
|
15
|
|
Total Current Liabilities |
71
|
74
|
59
|
52
|
41
|
40
|
33
|
31
|
20
|
17
|
|
Long-Term Debt |
299
|
313
|
308
|
92
|
43
|
37
|
36
|
36
|
4
|
4
|
|
Other Liabilities |
49
|
65
|
84
|
77
|
79
|
101
|
77
|
110
|
3
|
2
|
|
Total Liabilities |
419
-7%
|
452
+0%
|
451
+104%
|
220
+35%
|
164
-8%
|
178
+22%
|
146
-18%
|
178
+570%
|
27
+16%
|
23
N/A
|
|
Equity | |||||||||||
Common Stock |
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
4
|
0
|
|
Retained Earnings |
826
|
822
|
801
|
744
|
690
|
652
|
611
|
602
|
443
|
376
|
|
Additional Paid In Capital |
982
|
982
|
982
|
981
|
981
|
981
|
981
|
793
|
550
|
527
|
|
Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
27
|
|
Total Equity |
163
-2%
|
166
-11%
|
187
-23%
|
244
-18%
|
298
-11%
|
336
-11%
|
376
+92%
|
196
+77%
|
111
-38%
|
178
N/A
|
|
Total Liabilities & Equity |
582
-6%
|
618
-3%
|
638
+37%
|
464
+1%
|
462
-10%
|
514
-1%
|
522
+40%
|
374
+171%
|
138
-31%
|
201
N/A
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
76.8M
|
76.8M
|
76.7M
|
76.7M
|
76.7M
|
76.7M
|
76.7M
|
70.7M
|
76.7M
|
73.3M
|
Cash Flow Statement
Mar-2022 | Dec-2021 | Sep-2021 | Jun-2021 | Mar-2021 | Dec-2020 | Sep-2020 | Jun-2020 | Dec-2019 | ||
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||
Net Income |
(195)
|
(230)
|
(252)
|
(200)
|
(298)
|
(246)
|
(257)
|
(237)
|
(116)
|
|
Depreciation & Amortization |
3
|
3
|
3
|
2
|
3
|
2
|
2
|
2
|
2
|
|
Change in Deffered Taxes |
(30)
|
(26)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Non-Cash Items |
43
|
46
|
30
|
(19)
|
59
|
64
|
71
|
92
|
0
|
|
Cash Taxes Paid |
1
|
1
|
1
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
Cash Interest Paid |
6
|
5
|
4
|
4
|
3
|
2
|
2
|
0
|
0
|
|
Change in Working Capital |
(33)
|
(26)
|
(5)
|
7
|
12
|
12
|
1
|
4
|
(7)
|
|
Cash from Operating Activities |
(212)
+9%
|
(233)
-4%
|
(223)
-7%
|
(209)
+7%
|
(224)
-33%
|
(169)
+8%
|
(183)
-32%
|
(139)
-14%
|
(122)
N/A
|
|
Investing Cash Flow | ||||||||||
Capital Expenditures |
(7)
|
(6)
|
(7)
|
(6)
|
(3)
|
(3)
|
(2)
|
(1)
|
(2)
|
|
Other Items |
(1)
|
(0)
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
(0)
|
|
Cash from Investing Activities |
(7)
-12%
|
(7)
-1%
|
(7)
-16%
|
(6)
-63%
|
(3)
-23%
|
(3)
-19%
|
(2)
-145%
|
(1)
+57%
|
(2)
N/A
|
|
Financing Cash Flow | ||||||||||
Net Issuance of Common Stock |
0
|
1
|
(2)
|
189
|
433
|
433
|
436
|
244
|
102
|
|
Net Issuance of Debt |
267
|
267
|
268
|
49
|
61
|
62
|
62
|
62
|
(1)
|
|
Cash from Financing Activities |
267
+0%
|
267
+1%
|
266
+12%
|
238
-52%
|
495
0%
|
495
0%
|
497
+63%
|
306
+205%
|
101
N/A
|
|
Change in Cash | ||||||||||
Effect of Foreign Exchange Rates |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
|
Net Change in Cash |
48
+75%
|
27
-24%
|
36
+54%
|
23
-91%
|
268
-17%
|
324
+4%
|
312
+88%
|
166
N/A
|
(23)
N/A
|
|
Free Cash Flow | ||||||||||
Free Cash Flow |
(219)
+9%
|
(240)
-4%
|
(230)
-7%
|
(215)
+5%
|
(227)
-33%
|
(172)
+7%
|
(185)
-33%
|
(139)
-13%
|
(124)
N/A
|